Literature DB >> 18485137

Simvastatin: two decades in a circle.

Genovefa D Kolovou1, Anagnostopoulou Katerina, Vasiliadis Ioannis, Dennis V Cokkinos.   

Abstract

Simvastatin is an agent of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor group of drugs. It is administrated orally once a day in doses of 5-80 mg. Although its main action is to reduce total and low-density lipoprotein (LDL) cholesterol, it is able to reduce triglycerides and increase high-density lipoprotein cholesterol levels, though at a lower extent. Beyond this action, studies enrolled with simvastatin have shown beneficial effect on endothelial function, smooth muscle cell function, hemostasis, vascular wall function, LDL oxidation, and inflammation. All these actions mentioned above are known as pleiotropic effects. In this review, we will present all these effects, as well as the beneficial effects on atherogenesis and the reduction in cardiovascular morbidity and mortality related to simvastatin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18485137     DOI: 10.1111/j.1527-3466.2008.00047.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  9 in total

1.  Simvastatin protects photoreceptors from oxidative stress induced by all-trans-retinal, through the up-regulation of interphotoreceptor retinoid binding protein.

Authors:  Ting Zhang; Mark Gillies; Ying Wang; Weiyong Shen; Bobak Bahrami; Shaoxue Zeng; Meidong Zhu; Wenjuan Yao; Fanfan Zhou; Michael Murray; Ke Wang; Ling Zhu
Journal:  Br J Pharmacol       Date:  2019-05-11       Impact factor: 8.739

2.  The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbit.

Authors:  Wei Shen; Hai-Ming Shi; Wei-Hu Fan; Xin-Ping Luo; Bo Jin; Yong Li
Journal:  Mol Biol Rep       Date:  2010-11-25       Impact factor: 2.316

3.  Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.

Authors:  Paul A Lapchak; Moon Ku Han
Journal:  Brain Res       Date:  2010-05-19       Impact factor: 3.252

Review 4.  Update on statin-mediated anti-inflammatory activities in atherosclerosis.

Authors:  Fabrizio Montecucco; François Mach
Journal:  Semin Immunopathol       Date:  2009-05-05       Impact factor: 9.623

Review 5.  Lipidomics in vascular health: current perspectives.

Authors:  Genovefa Kolovou; Vana Kolovou; Sophie Mavrogeni
Journal:  Vasc Health Risk Manag       Date:  2015-06-12

6.  CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin.

Authors:  Genovefa Kolovou; Vana Kolovou; Georgia Ragia; Constantinos Mihas; Olga Diakoumakou; Ioannis Vasiliadis; Sophie Mavrogeni; Vassiliki Vartela; Vangelis G Manolopoulos
Journal:  Genet Mol Biol       Date:  2015-05-01       Impact factor: 1.771

7.  Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin.

Authors:  Genovefa Kolovou; Georgia Ragia; Vana Kolovou; Constantinos Mihas; Niki Katsiki; Ioannis Vasiliadis; Sophie Mavrogeni; Vassiliki Vartela; Anna Tavridou; Vangelis G Manolopoulos
Journal:  Open Cardiovasc Med J       Date:  2014-02-07

8.  Comparative efficacy of pitavastatin and simvastatin in patients with hypercholesterolemia: a meta-analysis of randomized controlled clinical trials.

Authors:  Ning Ma; Lianqun Cui
Journal:  Drug Des Devel Ther       Date:  2015-03-31       Impact factor: 4.162

9.  Effects of simvastatin on serum adiponectin: a meta-analysis of randomized controlled trials.

Authors:  Weibin Chen; Zhuo Huang; Minghui Bi; Xuejing Xu; Nengjiang Zhao
Journal:  Lipids Health Dis       Date:  2017-03-13       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.